DDInter621 DDInter808
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and
Garlic allergenic extract is used in allergenic testing.
Edoxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenyl salicylate
Edoxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Edoxaban {u} may lead to a major life threatening interaction when taken with {v} Velpatasvir
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Edoxaban may lead to a major life threatening interaction when taken with Reteplase
Edoxaban may lead to a major life threatening interaction when taken with Velpatasvir